首页/数据集/Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC [CGH]

Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC [CGH]

ChEBI2015-01-30 更新2026-07-21 收录

肿瘤耐药机制

肿瘤基因变异

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-64765 数据链接链接失效反馈

官方服务：

资源简介：

Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC [CGH]

应用场景：

创建时间：

2015-01-30

肿瘤耐药机制

信号通路靶向治疗

Taxanes are widely used in chemotherapy, but intrinsic and acquired resistance limit the clinical outcomes. Studies showed tumor interaction with suppressive macrophages plays a key role in taxane res

NIAID Data Ecosystem80

PCGP Ph-likeALL SNP6 - samples

急性淋巴细胞白血病基因组

肿瘤基因变异

PCGP Ph-likeALL SNP6EGA dataset EGAD00010000598

NIAID Data Ecosystem80

Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens

肿瘤耐药机制

转录组药物响应

Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types

NIAID Data Ecosystem50

AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Homo sapiens

肿瘤耐药机制

组合治疗

EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors Overall design: NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tan

NIAID Data Ecosystem80

Gene expression data from rapamycin resistant and sensitive cell lines

肿瘤耐药机制

miRNA调控

The mammalian target of rapamycin (mTOR) is a central regulator of cell proliferation. Inhibitors of mTOR are being evaluated as anti-tumor agents. Given the emerging role of microRNAs (miRNAs) in tum

NIAID Data Ecosystem70

Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC [CGH]

资源简介：

相关数据集